" class="no-js "lang="en-US"> VistaPath Raises $4M to Modernize Pathology Labs Using Computer Vision and Artificial Intelligence - Medtech Alert
Wednesday, June 19, 2024

VistaPath Raises $4M to Modernize Pathology Labs Using Computer Vision and Artificial Intelligence

VistaPath, the leading provider of artificial intelligence (AI)-based, data-driven pathology processing platforms, today announced that it has secured $4 million in seed funding led by Moxxie Ventures with participation from NextGen Venture Partners and First Star Ventures. With this latest round, VistaPath will further advance its mission to modernize pathology labs, delivering faster, more accurate diagnoses that lead to optimal patient care.

“We’re excited to be working with investors who share our desire to impact the lives and clinical outcomes of patients. This funding will support full-scale development and delivery of our innovative products, as well as the expansion of our operational and technical capabilities—allowing us to better serve the clinical and life science markets,” says Timothy Spong, CEO of VistaPath.

VistaPath’s Sentinel is a first-of-its-kind pathology processing platform designed to seamlessly deliver a range of solutions for critical lab processes. The company’s first application, released in 2021, is a tissue grossing platform that automates the process of receiving, assessing, and processing tissue samples. The platform uses a high-quality video system combined with AI to assess specimens and create a gross report 93% faster than human technicians with 43% more accuracy. Additional applications are slated to be released later this year.

“Pathology is the study of disease and connects every aspect of patient care. We believe that advances in computer vision and AI can bring great improvements to the pathology industry and ultimately lead to better outcomes for patients. We believe the team at VistaPath is building a best-in-class product for pathology labs and are proud to lead this investment round”, says Alex Roetter, General Partner at Moxxie Ventures.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more